

**Food Derived bioactive peptides for Health Enhancement and Management of  
Some Chronic Diseases**

*Abstract*

The bioactive peptides produced by enzymatic hydrolysis, acid hydrolysis and fermentation approach have been identified and used in enhancement or prevention and management of chronic diseases that are ravaging the world such as T2D, hypertension, oxidative stress, cancer, and obesity . Sources of bioactive peptides have been established ranging from plant to animal and marine foods that has pharmacological effects however depends on target cells and peptides structure and conformations. Plants such as hemp and animal source such as milk among others validate the findings of in vitro and in-vivo studies and the efficiency of these bioactive peptides. This article reviews the literature on BAPs with concerns on food sources, production and BAPS application in enhancement of health and management of hypertension, diabetes and oxidative stress. However, future research efforts on bioactive peptides should be directed towards elucidating specific sequenced bioactive peptides and their molecular mechanisms, through in-vivo and in-vitro studies for specific health conditions in human using nutrigenomics and peptideomic approaches.

**Keywords;** Food, bioactive peptides, Health, management, hypertension, oxidative stress, diabetes

**Introduction.**

The human system is subjected to physiological imbalance arising from entropy of the environment allowing extraneous toxic substances that burges normal human system and functions, leading to various health situations. Some artificial contaminants absorbed in protein and lipids from bioaccumulation in plant or animal proteins sources can also raise health risks and cause some chronic diseases such as cancer. Such aberration could be controlled by physiological hemostasis (Chubuikie et al., 2012) as well as health promoting agents (Ames et al., 1993)

31 The World Health Organization (WHO) reported about 36 million deaths, resulting from non-  
32 communicable diseases, including cardiovascular diseases, diabetes, cancers and chronic  
33 respiratory diseases (WHO, 2011). Over the decades, there has been research on bioactive protein  
34 hydrolysates and peptides derived from food, which had displayed broad scope of functions but  
35 less potent in their effects than synthetic pharmaceutical drugs (Mine et al., 2010). Nutrients and  
36 non-nutrient portions of food have been used to combat some of the physiological imbalance for  
37 decade with less or no improvements on chronic diseases except maintaining health status. This  
38 situation has emerged functional foods and nutraceuticals (Molecular nutrition) as an approach to  
39 prevention and management of human physiological imbalance or disease at gradual incremental  
40 intake maintaining optimal health (Kris Etherton, 2002). Dietary proteins exert much functionality  
41 in vivo by means of biologically active peptides. Such peptides are inactive within the sequence  
42 of the parent protein and which are sometimes released by digestive enzymes during  
43 gastrointestinal transit or by fermentation or ripening during food processing.

44 Bioactive peptides are usually encrypted in the amino acid sequences of food proteins (Korhonen  
45 and Pihlanto, 2003). Peptides have been defined as specific protein fragments that have a positive  
46 impact on body functions or conditions and may ultimately influence health (Kitts and Weiler,  
47 2003; Girgih 2013). These bioactive compounds are molecules or compounds which are active in  
48 living organisms, cells or tissues. They contain different kinds of essential molecules which may  
49 cure different kinds of diseases of living cells as well, supply proper nutrition to the living  
50 organisms (Kepiniski et al., 2006; Girgih et al., 2013). Peptides from hemp seed, chicken skin, soy  
51 whey and casein proteins has been elucidated by enzymatic hydrolysis as a potent antioxidants  
52 and antihypertensive agents (Girgih et al., 2013; Onuh, 2013). Its peptide structure, antioxidant as  
53 well as ACE and renin inhibitory actions has been established in vivo and in vitro, hence a  
54 potential pharmaceutical products for health enhancement (Girgih et al., 2013). BAPS from  
55 milks has been established to regulate Alpha-glucosidase and dipeptidyl peptidase IV (DPP-IV)  
56 enzymes in T2D via satiety response, regulation of incretin hormones and these have been  
57 found to reduce the activity of carbohydrate degrading digestive enzymes. (Prasad et al., 2015;  
58 Power et al., 2014). Similarly, peptides from skin gelatin, against DPP-IV inhibition had also been  
59 established (Patil and others 2015). Atlantic salmon skin gelatin was found to be a potent material  
60 exerting the DPP-IV-inhibiting effect. This effect was confirmed in both hydrolysates produced  
61 with different proteases as well as peptides fractionated by ultrafiltration.

62 BAP have been captured by food processors, genomic engineers and the industries, and had  
63 identified production of bioactive peptides from plant and animal sources. These active bioactive  
64 peptides have potential pharmaceutical properties beyond adequate nutrition. Applications of  
65 bioactive peptides are gaining attention at different areas such as supplementation, fortification,  
66 proteomic and peptideomic studies. Derived peptides play critical role in human living cells.  
67 From dietary point of view, peptides are more bioavailable than proteins or free amino acids  
68 (Shimuzu et al., 2005). They have less side effect than pharmaceutical drugs, hence potential  
69 alternative to pharmaceutical drugs

70 The review seeks to elucidate bioactive peptides and their mechanisms of actions originating from  
71 plant and animal food sources that exhibit bio activities typical of enhancing and management of  
72 chronic disease such as hypertension, diabetic and oxidative stress.

### 73 **THE FOOD SOURCE OF BIOACTIVE PEPTIDES**

74 Food protein sources for BAPS come from animal and plant .Food protein from plants includes  
75 soybean, legumes, pea's hempseed, pulse, oat wheat conola and flaxseed. BAPS could also come  
76 from waste food materials. Food protein bioactive peptides from animal sources includes milk,  
77 (casein and whey), egg,meat muscle, caterpillars, termites. Marine sources includes; salmon,  
78 oysters, jelly fish, (Chuibuike et a.,2012 ; Girgih et al.,2011).Peptide fractions from food sources  
79 have been established, IPP and VPP from milk (Mizushima et al., 2004); ESIINF and IVF  
80 fractions from egg (Miguel et al ,2007; Miguel et al., 2005); IKW and LKP from chicken  
81 muscles (Fujita et al ,. 2000); VKKVLGNP and KRQKYDI. Plant sources of bioactive peptides  
82 are numerous including DLP and DG from soy proteins (Wu and Ding, 2001; Wu and Ding,  
83 2002); LQP and IQP from wheat bran (Nogata et al., 2011); KF and EF from pea (Li and Aluko,  
84 2010); LY and RALP from rapeseed (He et al., 2013); VF and KY from Wakame (Suetsuna et  
85 al., 2004); LRP and LSP from maize (Puchalska et al., 2013); KDYRL and VTPALR from mung  
86 bean (Li et al., 2006); WNI, LNA, QGR and RW from flaxseed (Marambe et al., 2011;  
87 Udenigwe et al., 2012); EVPK and VVGAK fractions from sweet potato (Huang et al., 2011) as

88 well as from mushroom and pumpkin, most of this fractions have multi-functional properties for  
 89 health enhancement.( Table 1.)

90 According to (Chuibuike et al.,2012, Girgih 2011) choice of bioactive peptides food  
 91 sources are based on value addition from underutilized rich protein sources and the utilization of  
 92 specific amino acid for particular medical formulation. Recently a Nano based approach have  
 93 been proposed to predict protein sources (Gu et al ,.2011), which could lead to excellent selection  
 94 of rich food protein sources for bioactive peptides production.

96 Table 1; **BAPS from plant origins**

97 <b>Protein</b>	Enzyme	Peptides /Function /Sequence	Health Effect	Reference
98 <b>Plant source;</b>				
100 Hemp seed.	Proteolytic enzyme	Inhibit ACE	Anti- hypertensive	Girgih et al., 2011
103 Pea seed	Alcalase	InhibitACE (IR,KFand EF)	Anti- hypertensive	Huan et al., 2010
106 Soyabean.	Enymatic Hydrolysis	Anti- hypocholesterol (Leu-pro-try-pro)	cholesterol reduction	Zhang et al., 2007
109 Wheat glutein	Aspergillus Oryzae Protease. Hydrolylate and fractions	Pyroglutamyl leucine	Anti – inflammatory and mucosal Improvement	Sato etal ,. 2013
115 Black bean	Enzymatic hydrolysis	Inhibit glucose transport (AKSPLF,ATNPLE FEELN, LSVSVL)	Reduce blood pressure	Chakraor et al., 2014

119  
120  
121  
122  
123

124 **Table 2: BAPS from animal origins**

125

126	<b>Protein</b>	<b>Enzyme</b>	<b>Peptides /Function /Sequence</b>	<b>Health Effect</b>	<b>Reference</b>
128	<b>Animal source:</b>				
129	Oyster	Protease soln from	Anti -tumor (peptide <3Kda)	Multi-functional ppty	Wang et al., 2010
132	Jelly fish	Bacillus spp protamex	D-glucose induced aging	Anti- oxidant	Ding et al., 2011
134	Collagen		Immune booster	multifunctional	Yanget al., 2010
135	Salmon	protease		Immune stimulation	Wang et al., 2008
137	Insect)	Enzyme hydrolysis	High inhibitory activity on ACE	ACE inhibitory drugs	Cito et al., 2017
138	(silkworm)	Acid hydrolysis			Onuh,2015
141	Chicken	Acalase	Inhibitory on ACE Protein	InhibitACE scavenging activity	
142	Skin		Kda <1,1-3,3-5,5-10)		
145	Crabs	protamex	Cancer Inhibition	Anti- tumor	Doyen et al ,. 2011
148	Shrimp	Cryotin	Cancer Inhibition	Anti –Cancer	Kannon etal., 2011
149	shell				
150	By products				
151	enzyme				

152

153 **Production of Bioactive Peptides**

154 Research of recent years has shown that dietary proteins provide a rich source of biologically  
 155 active peptides. Bioactive peptides are produced from precursor proteins where they occur as  
 156 inactive amino acid sequences but can be released using the following methods:

- 157 (a) enzymatic hydrolysis by digestive enzymes,
- 158 (b) fermentation of precursor proteins with proteolytic starter cultures and
- 159 (c) proteolysis by enzymes derived from microorganisms or plants (Korhonen & Pihlanto, 2007).


160 The activity of peptides is based on their inherent amino acid composition and sequence and their  
 161 size could range from 2 to 20 amino acid residues.

162 The production and processing of bioactive peptides from animal source and plant varies. The  
 163 production of baps from animal source require hydrolysis as the major stage, however plant

164 source of baps require isolation and hydrolysis, this two major stages in plant baps may be due to  
 165 attached side chain moieties in plant tissues.

166

167 Fig 1:



187 Bioactive peptides are attached on the primary structure of plant and animal cells as an in active  
 188 amino acid sequence which can be released by fermentation, enzymatic hydrolysis, and acid  
 189 hydrolysis and via food processing. These methods of releasing the primary amino acid could be  
 190 done in-vivo or in-vitro (Aluko, 2008). The release of these bio actives hydrolysate and peptides  
 191 have shown a better bioactivity than parent protein across enterocytes or intestinal walls and to  
 192 target cells (Chuibuke et al .,2012;Girgih et al.,2011).


193 The major and common method of PABS production is by enzymatic hydrolysis, acid and  
 194 fermentation methods. Peptides could be released from food source hydrolytically using single,  
 195 multiple or specific or non -specific mimic digestive proteases. This approached has been  
 196 established in-vitro and in-vivo (Chubuike at al .,2012 Girgih et al. 2011 ;Onuh, 2012).The  
 197 release of peptides by this approached are factored by enzyme selection, hydrolysis time degree of

198 hydrolysis substrate enzyme ration and pretreatments (Chubuikie at al ,2012 Girgih et al,. 2011 )  
199 .Sonication, Thermal treatment , hydrostatic pressure can increase enzyme protein interactions(  
200 Inouge et al,. 2009.Quiro et al,. 2007; Wu and Mgunder, 2009).

### 201 **Enzymatic Hydrolysis of Peptides.**

202 Enzymatic hydrolysis has been the common way of producing bioactive peptide with trypsin  
203 activity on ACE inhibition (Marayama et al ,. 1982. Berrocal et al ,. 1989). Other enzymes and  
204 their combination for bioactive peptide include proteolytic enzyme ( Alcalase , chymotrypsin,  
205 pancreatin and pepsin ).However, more than a single proteolytic enzyme can be used for  
206 hydrolysis in peptide formation via stepwise or simultaneous approaches .See (fig 2). The  
207 formation of peptide using this approach is a function of  $P^H$ , Temperature and Time. (Sangsawad  
208 et al,. 2007). There are no established peptide products of food from a proteolytic enzyme but  
209 chain length and molecular weight determine peptide functionality.( Zhang et al,. 2017 ; Hauang  
210 et al ,.2017). Low molecular weight peptides (<10ka) have been found more effective against  
211 oxidative stress and hypertension.(Girgih et al 2011;Onuh,2013).

212 Fig 2



228 Adopted by ( Tang et al,. 2006)

229


### Microbial Fermentation

230

**Fermentation using** microorganism for bioactive peptide production involves the use of selective or combined strains of yeast, bacterial or fungi to make culture which PH and temperature dependent. During microbial fermentation harvesting, increasing surface area before hydrolysis depends on strain of microorganism used, protein source and fermentation time. Fig 3( Eric et al ,2017 Ahn et al ,2009).Bioactive peptides from whey fermented by lactobacillus brevis had strong inhibitory ACE ability than other lactobacillus strains.This strain selectivity was observed by( Matar et al,. 2003;fitzgerald and Murrey , 2006,Gobbetti et al,. 2007).Yoghurt and cheese starter and probiotic have been discovered to produce bioactive peptide in milk during fermentation Gomez ruizeetal,. 2002 ;Dankor et al,. 2007)

239

240 Fig 3



247

248

249

250

### Bioactive Peptides in the prevention and Management of Hypertension.

251

Studies conducted to evaluate the antihypertensive potentials of food derived peptides from natural foods of plant and animal origin and the ability of these peptides to prevent or treat hypertension have been carried out *in vitro* (Hernández-Ledesma et al,2011; Jauhiainen & Korpela, 2007; Murray and Fitzgerald, 2007). The potential antihypertensive effect of a peptide depends structurally on intactness and active form, resistance to cleavage by digestive proteinases and peptidases, and transportation through the brush border membrane without loss of integrity(Girgih et al,2011).Although, the blood pressure lowering effect of most bioactive peptides is less than that of pharmaceutical drugs, the negative side effects associated with the

252

253

254

255

256

257

258



259 long-term use of antihypertensive drugs is causing a gradual shift of attention to natural food  
260 protein-derived peptides.

261 Natural food protein-derived peptides with potent ACE-inhibitory activity have attracted much  
262 attention and a large number of these peptides that exhibit various amino acid sequences have  
263 been isolated and characterized from enzymatic hydrolysates of foods, such as grass carp fish,  
264 oysters, gelatin, egg, milk, whey peptides (Hernández-Ledesma et al., 2011; Zhang et al., 2009))  
265 Chicken peas and yellow peas using Alcalese and papain hydrolysates has been reported to  
266 inhibited ACE in-vitro (Barbana et al., 2010). Eggs using thermolysin and alcalase was also  
267 reported to effect ACE inhibitory activity (You et al., 2011). Animal protein peptides from pork  
268 meat has been established via oral administration of its fractions RPR, KKAPVA, PTPVP with  
269 RPR fractions exerting more ACE inhibitory vivo activity (Escudero et al., 2012).

270 The renin-angiotensin-aldosterone system (RAAS) plays a major role in the regulation of blood  
271 pressure and normal heart function (Figure 4). Renin is an aspartyl protease that catalyzes the  
272 conversion of angiotensinogen to angiotensin I (AT I) (Erdmann et al., 2007; Nagpal et al., 2010,  
273 Phelan et al., 2011). Subsequently, ACE (a peptidyl dipeptide hydrolase, EC 3.4.15.1) catalyzes  
274 the conversion of AT I to angiotensin II (AT II) leading to constriction of the blood vessels, hence  
275 an increase in blood pressure. ACE also inactivates the activity of the potent vasodilator,  
276 bradykinin 6 and subsequently results in an increase in blood pressure (Erdmann et al., 2007).  
277 Thus, the inhibition of ACE is a crucial target for antihypertensive activity.

278 The mechanism involved in modulating the renin-angiotensin system (RAS) that controls blood  
279 pressure is critical for the prevention or treatment of hypertension. ACE alone does not  
280 completely prevent production of Angiotensin II, the vasoconstrictor which is continually  
281 produced from an ACE independent pathway catalyzed by chymase (Fig. 4). The most studied BP  
282 control pathways with regard to food-derived peptides involve those shown to inhibit ACE and  
283 renin enzymes *in vitro*. These enzymes are the main regulators of BP and are both involved in the  
284 renin-angiotensin system (RAS), in addition ACE is also involved in the kinin-nitricoxide system  
285 (KNOS). Inhibition of ACE and renin in these systems leads to relaxation of the artery walls  
286 (vasodilation) and subsequent lowering of BP.

287

288

289

290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323

## Mechanism of hypertension




Fig 4; Mechanism and Intervention on hypertension by bioactive peptides.

(Adopted from Girgih et al., 2013)

### Bioactive Peptides in the Management of Oxidative Stress (anti-oxidants)

Oxidative stress occurs as a result of imbalance between the production of free radicals, reactive oxygen species (ROS) and the scavenging ability of endogenous anti-oxidants. Excessive production of ROS may damage membranes, proteins, enzymes and DNA resulting in the development of chronic disease conditions (Girgih et al., 2011; Bidlingmeyer et al., 1984).

Enzymatic food protein-derived peptides, in comparison to synthetic compounds are believed to be safer natural antioxidants that can be used as protective agents to help the human body reduce oxidative damage and associated diseases (Girgih et al., 2011). The antioxidant properties of bioactive peptides, hydrolysates largely depend on enzyme specificity, degree of hydrolysis and the nature of the peptides released including molecular weight, amino acid composition and hydrophobicity (Gehrke et al., 1985; You et al., 2010). The antioxidant properties of peptides include their ability to scavenge free radicals, inhibit linoleic acid autoxidation, act as chelating


324 agents of metal ions, or as reducing agents (Tang et al.,2009) . The presence of certain amino  
325 acids like, histidine, tyrosine, methionine, lysine, tryptophan and proline increases the antioxidant  
326 potency of most food-derived peptides (Aluko and Monu , 2003) . It was found that overall,  
327 alcalase and proteinase-k were more efficient proteases in releasing bioactive peptides from  
328 rapeseed with potent antioxidant properties compared to combined pepsin + pancreatin,  
329 flavourzyme and thermolysin (He et al., 2013). Several other natural antioxidant peptides have  
330 been produced from soy proteins, sunflower, pea, chickpea, flaxseed, salmon, shark liver, beef,  
331 fish skin, milk and chicken bone. Studies have shown peptides with antioxidant property released  
332 from food sources, including cow's milk (Kumar et al., 2011), eggs (Chen et al., 2011), soy  
333 protein (Amadou et al., 2011), fish (Bougaterf et al., 2009, Najafian et al., 2011), wheat (Koo et  
334 al., 2011), marine rotifer (Byun et al., 2009), chickpeas (Yust et al., 2011) and African yam bean  
335 (Ajibola et al., 2011).

336 Several diseases have been proposed to be mediated by radical or oxidant species, it is valuable to  
337 learn about these antioxidant compounds that might block, inhibit, or prevent radical-initiated  
338 reactions as well as elucidate the mechanisms of their action (Krinsky, 1992). Knowledge of the  
339 various mechanisms by which bioactive peptides are able to achieve their roles as antioxidants in  
340 the prevention of oxidative stress related ailments abounds but specific tailored peptide sequences  
341 of desired amino acid composition with the potential to scavenge, reduce ROS/RNS/free radicals  
342 and chelate transition metals as well as act as lipid peroxidation agents are critical (Girgih et  
343 al.,2013).

344 However, several mechanisms of antioxidant action of food derived bioactive peptides against  
345 ROS/RNS and free radicals have been proposed (Dai and Mumper, 2010). These include: radical  
346 scavenging species such as ROS/RNS and free radicals by readily donating hydrogen atoms or  
347 electrons to quench their destructive effects on biomolecules, via peptide bonds and hydroxyl  
348 substituents. Secondly, by suppression of ROS/RNS and free radical formation via inhibition of  
349 certain pro-oxidant enzymes and chelating of transition metal ions that are involved in catalyzing  
350 free radical production. Thirdly, by upregulating the function of the antioxidant enzyme-linked  
351 defence mediated by endogenous antioxidants such as reduced glutathione (GSH), ascorbate,  
352 superoxide dismutase and catalase (Duthie et al., 2006) or enzyme modulation of cellular  
353 physiological and biochemical reactions (Vattem et al., 2005). Fig. 5 illustrates the initiation of  
354 ROS/free radical production, their destructive effects on cellular organelles leading to the

355 development of chronic diseases and the use of bioactive peptides as an intervention strategy. The  
 356 initiating species for the production of ROS/free radicals is superoxide radical which is converted  
 357 to hydrogen peroxide that could be broken down into harmless metabolites such as water and  
 358 oxygen in the presence of endogenous antioxidants including superoxide dismutase, catalase,  
 359 glutathione etc. In disease state, excessive ROS/free radicals are produced and the body's natural  
 360 mechanism to inactivate them is overwhelmed resulting in the conversion of hydrogen peroxide to  
 361 the most toxic radical called hydroxyl radical. This reaction is catalyzed by transition metals  
 362 ( $\text{Cu}^{2+}$  and  $\text{Fe}^{2+}$ ). If the situation is not attended to, the harmful radicals begin to damage tissues,  
 363 cell membranes, proteins, enzymes, and DNA, which leads to the progression of chronic diseases  
 364 such as diabetes, cancer, obesity and can cause adverse cardiovascular events.

365



372 **Fig 5;** possible mechanisms of action of bioactive peptides in oxidative condition  
 373 (Adapted from Young and Woodside, 2001)


374

### 375 **Bioactive Peptides in Diabetic Prevention and Management**

376 Diabetes mellitus (DM), a chronic metabolic disorder caused by defective insulin production  
 377 characterized by hyperglycemia, a condition in which surplus of sugar is present in the blood  
 378 stream. Prevalence of diabetes mellitus is increasing markedly because of aging, population  
 379 growth, increasing urbanization, incidences of obesity, and more sedentary lifestyles. Type 1  
 380 diabetes (T1D) and Type 2 diabetes (T2D) are the main two types of diabetes. Though the latter is  
 381 much more common and accounts for 90-95 % of all diabetes. A number of factors, such as  
 382 insulin resistance, hyper insulinemia, impaired insulin secretion, reduced insulin mediated  
 383 glucose uptake, and utilization convoluted the treatment of T2D (Fig. 6). The regulation of

384 Alpha-glucosidase and dipeptidyl peptidase IV (DPP-IV) enzymes in T2D via satiety response,  
 385 regulation of incretin hormones regulations are the mechanism to reduce the activity of  
 386 carbohydrate degrading digestive enzymes.( Prasad et al.,2015; Power et al.,2014).Skin gelatin  
 387 against DPP-IV inhibition had been established (Patil and others 2015). Atlantic salmon skin  
 388 gelatin was found to be a potent material exerting the DPP-IV-inhibiting effect. This effect was  
 389 confirmed in both hydrolysates produced with different proteases as well as peptides fractionated  
 390 by ultrafiltration.

391  
 392  
 393



394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406

407 **Fig 6 ;Glucose mediation mechanism by bioactive peptides**

408

409 **CONCLUSION**

410 This review has shown that peptides derived through enzymatic, acidic and fermentation of plant  
 411 and animal food protein hydrolysates possesses bioactive materials that could on an incremental  
 412 bases stops the rate of cell damage that could arise from oxidative stress, enzymatic synthesis  
 413 (Renin agniostenes system RAS) hence management and prevention of hypertension, diabetes  
 414 and oxidative stress which are relevant to the sustenance of human health and physiological  
 415 stability. This area is growing with the discovery of new molecular nutrients for molecular disease  
 416 management. With a lot of information existing on the various bioactivities of food protein-  
 417 derived peptides, hence research should be directed toward evaluation of specific sequenced

418 peptides from varied sources in the management and prevention of some chronic disease  
419 peptideomically, its bioavailability, and for making specific functional foods and pharmaceutical  
420 drugs.

421

422 Reference.

423 Ajibola, C. F., Eleyinmi, A. F., & Aluko, R. E. (2011). Kinetics of the inhibition of renin and  
424 angiotensin I converting enzyme by polar and non-polar polyphenolic extracts of *Vernonia*  
425 *amygdalina* and *Gongronema latifolium* leaves. *Plant Foods for Human Nutrition*, 66(4),  
426 320-327.

427 Bhutia, S. K., & Maiti, T. K. (2008). Targeting tumors with peptides from natural sources. *Trends*  
428 *in Biotechnology*, 26(4), 210-217.

429 Billyard, T., McTernan, P., & Kumar, S. (2007). Potential therapies based on antidiabetic  
430 peptides. *Best Practice and Research: Clinical Endocrinology and Metabolism*, 21(4),  
431 641-655.

432 Borer, J. S. (2007). Angiotensin-converting enzyme inhibition: A landmark advance in treatment  
433 for cardiovascular diseases. *European Heart Journal, Supplement*, 9(E), E2-E9.

434 Chen, G. T., Zhao, L., Zhao, L. Y., Cong, T., & Bao, S. F. (2007). In vitro study on antioxidant  
435 activities of peanut protein hydrolysate. *Journal of the Science of Food and Agriculture*,  
436 87(2), 357-362.

437 Choi, K. Y. G., & Mookherjee, N. (2012). Multiple immune-modulatory functions of cathelicidin  
438 host defense peptides. *Frontiers in Immunology*, 3(JUN):49

439 Cifarelli, V., Trucco, M., & Luppi, P. (2011). Anti-inflammatory effects of C-peptide prevent  
440 endothelial dysfunction in Type 1 diabetes. *Immunology, Endocrine and Metabolic Agents*  
441 *in Medicinal Chemistry*, 11(1), 59-70.

442 Crowley, S. D., & Coffman, T. M. (2012). Recent advances involving the renin-angiotensin  
443 system. *Experimental Cell Research*, 318(9), 1049-1056.

444 Fitzgerald, C., Mora-Soler, L., Gallagher, E., O'Connor, P., Prieto, J., Soler-Vila, A., & Hayes, M.  
445 (2012). Isolation and characterization of bioactive pro-peptides with in Vitro renin  
446 inhibitory activities from the macroalga (*Palmaria palmata*). *Journal of Agricultural and*  
447 *Food Chemistry*, 60(30), 7421-7427.

448 Girgih, A. T., Udenigwe, C. C., Hasan, F. M., Gill, T. A., & Aluko, R. E. (2013). Antioxidant  
449 properties of salmon (*Salmo salar*) protein hydrolysate and peptide fractions isolated by  
450 reverse-phase HPLC. *Food Research International*, 52(1), 315-322.

451 Girgih, A. T., Udenigwe, C. C., Li, H., Adebisi, A. P., & Aluko, R. E. (2011). Kinetics of enzyme  
452 inhibition and antihypertensive effects of hemp seed (*Cannabis sativa* L.) protein  
453 hydrolysates. *JAOCS, Journal of the American Oil Chemists' Society*, 88(11), 1767-1774.

454 Haidet, J., Cifarelli, V., Trucco, M., & Luppi, P. (2009). Anti-inflammatory properties of C-  
455 peptide. *Review of Diabetic Studies*, 6(3), 168-179.

456 Harel, Z., Gilbert, C., Wald, R., Bell, C., Perl, J., Juurlink, D., Beyene, J., & Shah, P. S. (2012).  
457 The effect of combination treatment with aliskiren and blockers of the renin-angiotensin  
458 system on hyperkalaemia and acute kidney injury: Systematic review and meta-analysis.  
459 *BMJ (Online)*, 344(7842).

460 Hartmann, R., & Meisel, H. (2007). Food-derived peptides with biological activity: from research  
461 to food applications. *Current Opinion in Biotechnology*, 18(2), 163-169.

462 He, R., Malomo, S. A., Alashi, A., Girgih, A. T., Ju, X., & Aluko, R. E. (2013). Purification and  
463 hypotensive activity of rapeseed protein-derived renin and angiotensin converting enzyme  
464 inhibitory peptides. *Journal of Functional Foods*.

465 Hoskin, D. W., & Ramamoorthy, A. (2008). Studies on anticancer activities of antimicrobial  
466 peptides. *Biochimica et Biophysica Acta - Biomembranes*, 1778(2), 357-375.

467 Huang, F. J., & Wu, W. T. (2010). Purification And Characterization Of A New Peptide (S-8300)  
468 From Shark Liver. *Journal of Food Biochemistry*, 34(5), 962-970.

469 John, S., Thangapandian, S., Arooj, M., Hong, J. C., Kim, K. D., & Lee, K. W. (2011).  
470 Development, evaluation and application of 3D QSAR Pharmacophore model in the  
471 discovery of potential human renin inhibitors. *BMC bioinformatics*, 12 Suppl 14.

472 Kobayashi, Y., Yamauchi, T., Katsuda, T., Yamaji, H., & Katoh, S. (2008). Angiotensin-I  
473 converting enzyme (ACE) inhibitory mechanism of tripeptides containing aromatic  
474 residues. *Journal of Bioscience and Bioengineering*, 106(3), 310-312.

475 Korhonen, H., & Pihlanto, A. (2006). Bioactive peptides: Production and functionality.  
476 *International Dairy Journal*, 16(9), 945-960.

477 Li, H., & Aluko, R. E. (2005). Kinetics of the inhibition of calcium/calmodulin-dependent protein  
478 kinase II by pea protein-derived peptides. *Journal of Nutritional Biochemistry*, 16(11),  
479 656-662.

480 Li, H., & Aluko, R. E. (2010). Identification and inhibitory properties of multifunctional peptides  
481 from pea protein hydrolysate. *Journal of Agricultural and Food Chemistry*, 58(21),  
482 11471-11476.



483 Madureira, A. R., Tavares, T., Gomes, A. M. P., Pintado, M. E., & Malcata, F. X. (2010). Invited  
484 review: Physiological properties of bioactive peptides obtained from whey proteins.  
485 *Journal of Dairy Science*, 93(2), 437-455.

486 Martínez-Maqueda, D., Miralles, B., Recio, I., & Hernández-Ledesma, B. (2012).  
487 Antihypertensive peptides from food proteins: A review. *Food and Function*, 3(4), 350-  
488 361.

489 Quiñones, M., Sánchez, D., Mugerza, B., Moulay, L., Laghi, S., Miguel, M., & Aleixandre, A.  
490 (2010). Long-term intake of CoccoanOX attenuates the development of hypertension in  
491 spontaneously hypertensive rats. *Food Chemistry*, 122(4), 1013-1019.

492 Regazzo, D., Da Dalt, L., Lombardi, A., Andrighetto, C., Negro, A., & Gabai, G. (2010).  
493 Fermented milks from *Enterococcus faecalis* TH563 and *Lactobacillus delbrueckii* subsp.  
494 *bulgaricus* LA2 manifest different degrees of ACE-inhibitory and immunomodulatory  
495 activities. *Dairy Science and Technology*, 90(4), 469-476.

496 Seil, M., Nagant, C., Dehaye, J. P., Vandenbranden, M., & Lensink, M. F. (2010). Spotlight on  
497 human LL-37, an immunomodulatory peptide with promising cell-penetrating properties.  
498 *Pharmaceuticals*, 3(11), 3435-3460.

499 Shu, M., Cheng, X., Zhang, Y., Wang, Y., Lin, Y., Wang, L., & Lin, Z. (2011). Predicting the  
500 activity of ACE inhibitory peptides with a novel mode of pseudo amino acid composition.  
501 *Protein and Peptide Letters*, 18(12), 1233-1243.

502 Staljanssens, D., Van Camp, J., Herregods, G., Dhaenens, M., Deforce, D., Van De Voorde, J., &  
503 Smagghe, G. (2011). Antihypertensive effect of insect cells: In vitro and in vivo  
504 evaluation. *Peptides*, 32(3), 526-530.

505 Thangapandian, S., John, S., Sakkiah, S., & Lee, K. W. (2011). Potential virtual lead  
506 identification in the discovery of renin inhibitors: Application of ligand and structure-  
507 based pharmacophore modeling approaches. *European Journal of Medicinal Chemistry*,  
508 *46*(6), 2469-2476.

509 Udenigwe, C. C., Li, H., & Aluko, R. E. (2012). Quantitative structure-activity relationship  
510 modeling of renin-inhibiting dipeptides. *Amino Acids*, *42*(4), 1379-1386.

511 Udenigwe, C. C., Lin, Y. S., Hou, W. C., & Aluko, R. E. (2009). Kinetics of the inhibition of  
512 renin and angiotensin I-converting enzyme by flaxseed protein hydrolysate fractions.  
513 *Journal of Functional Foods*, *1*(2), 199-207.

514 Wang, G. T., Chung, C. C., Holzman, T. F., & Krafft, G. A. (1993). A continuous fluorescence  
515 assay of renin activity. *Analytical Biochemistry*, *210*(2), 351-359.

516 Wang, X. Y., Wang, J., Hu, Y., Lin, Y., Shu, M., Wang, L., Cheng, X. M., & Lin, Z. H. (2011).  
517 Predicting the activity of peptides based on amino acid information. *Journal of the*  
518 *Chinese Chemical Society*, *58*(7), 877-883.

519 Wang, Z., Zhang, S., Jin, H., Wang, W., Huo, J., Zhou, L., Wang, Y., Feng, F., & Zhang, L.  
520 (2011). Angiotensin-I-converting enzyme inhibitory peptides: Chemical feature based  
521 pharmacophore generation. *European Journal of Medicinal Chemistry*, *46*(8), 3428-3433.

522 Wood, J. M., Maibaum, J., Rahuel, J., Grütter, M. G., Cohen, N. C., Rasetti, V., Rüger, H.,  
523 Göschke, R., Stutz, S., Fuhrer, W., Schilling, W., Rigollier, P., Yamaguchi, Y., Cumin, F.,  
524 Baum, H. P., Schnell, C. R., Herold, P., Mah, R., Jensen, C., O'Brien, E., Stanton, A., &  
525 Bedigian, M. P. (2003). Structure-based design of aliskiren, a novel orally effective renin  
526 inhibitor. *Biochemical and Biophysical Research Communications*, *308*(4), 698-705.

527 Wu, J., Aluko, R. E., & Nakai, S. (2006). Structural requirements of angiotensin I-converting  
528 enzyme inhibitory peptides: Quantitative structure-activity relationship study of Di- and  
529 tripeptides. *Journal of Agricultural and Food Chemistry*, 54(3), 732-738.

530 Wu, J. M., Jan, P. S., Yu, H. C., Haung, H. Y., Fang, H. J., Chang, Y. I., Cheng, J. W., & Chen,  
531 H. M. (2009). Structure and function of a custom anticancer peptide, CB1a. *Peptides*,  
532 30(5), 839-848.

533 Xie, Z., Huang, J., Xu, X., & Jin, Z. (2008). Antioxidant activity of peptides isolated from alfalfa  
534 leaf protein hydrolysate. *Food Chemistry*, 111(2), 370-376.

535 Young, D., Fan, M. Z., & Mine, Y. (2010). Egg yolk peptides up-regulate glutathione synthesis  
536 and antioxidant enzyme activities in a porcine model of intestinal oxidative stress. *Journal*  
537 *of Agricultural and Food Chemistry*, 58(13), 7624-7633.

538 Yuan, L., Wu, J., Aluko, R. E., & Ye, X. (2006). Kinetics of renin inhibition by sodium  
539 houthuyfonate analogs. *Bioscience, Biotechnology and Biochemistry*, 70(9), 2275-2280.

540 Zhu, C. F., Li, G. Z., Peng, H. B., Zhang, F., Chen, Y., & Li, Y. (2010). Effect of marine collagen  
541 peptides on markers of metabolic nuclear receptors in type 2 diabetic patients with/without  
542 hypertension. *Biomedical and Environmental Sciences*, 23(2), 113-120.

543

544

545

546